N-arachidonyl-glycine modulates synaptic transmission in superficial dorsal horn.

PubWeight™: 0.86‹?›

🔗 View Article (PMC 2992905)

Published in Br J Pharmacol on October 01, 2010

Authors

Hyo-Jin Jeong1, Robert J Vandenberg, Christopher W Vaughan

Author Affiliations

1: Pain Management Research Institute, Kolling Institute of Medical Research, Northern Clinical School, University of Sydney at Royal North Shore Hospital, NSW, Australia. jeong@med.usyd.edu.au

Articles cited by this

Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature (1987) 8.89

Guide to Receptors and Channels (GRAC), 4th Edition. Br J Pharmacol (2009) 8.07

Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature (2001) 6.12

GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science (2004) 3.38

Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J Biol Chem (2001) 2.19

Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett (2000) 2.11

Glycinergic neurons expressing enhanced green fluorescent protein in bacterial artificial chromosome transgenic mice. J Comp Neurol (2005) 2.05

Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem (1997) 2.01

Deletion of the mouse glycine transporter 2 results in a hyperekplexia phenotype and postnatal lethality. Neuron (2003) 1.97

Presynaptic glycine receptors enhance transmitter release at a mammalian central synapse. Nature (2001) 1.94

Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem (2009) 1.91

Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition. Neuron (2003) 1.84

Glycine transporters are differentially expressed among CNS cells. J Neurosci (1995) 1.81

Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. Biochem Biophys Res Commun (2006) 1.79

N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci (2010) 1.78

Neuronal and glial glycine transporters have different stoichiometries. Neuron (2000) 1.72

Development of glycinergic synaptic transmission to rat brain stem motoneurons. J Neurophysiol (1998) 1.59

In vivo patch-clamp analysis of IPSCs evoked in rat substantia gelatinosa neurons by cutaneous mechanical stimulation. J Neurophysiol (2000) 1.52

The glycinergic control of spinal pain processing. Cell Mol Life Sci (2005) 1.52

Oxidative metabolism of anandamide. Prostaglandins Other Lipid Mediat (2000) 1.50

Excitatory interneurons dominate sensory processing in the spinal substantia gelatinosa of rat. J Physiol (2007) 1.46

Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol (2003) 1.38

Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. J Biol Chem (2008) 1.37

Junctional versus extrajunctional glycine and GABA(A) receptor-mediated IPSCs in identified lamina I neurons of the adult rat spinal cord. J Neurosci (1999) 1.29

The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways. BMC Biochem (2009) 1.28

Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J Biol Chem (2009) 1.27

N-Arachidonyl-glycine inhibits the glycine transporter, GLYT2a. J Neurochem (2006) 1.18

T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids. J Neurosci (2009) 1.18

Actions of N-arachidonyl-glycine in a rat neuropathic pain model. Neuropharmacology (2007) 1.17

Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. J Physiol (2004) 1.14

The time course of transmitter at glycinergic synapses onto motoneurons. J Neurosci (2008) 1.14

Facilitation of spinal NMDA receptor currents by spillover of synaptically released glycine. Science (2003) 1.13

Selective oxygenation of N-arachidonylglycine by cyclooxygenase-2. Biochem Biophys Res Commun (2002) 1.12

Slow glycinergic transmission mediated by transmitter pooling. Nat Neurosci (2009) 1.11

A structure-activity relationship study on N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun (2004) 1.05

Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine. Biochem Pharmacol (2008) 1.05

N-arachidonoyl glycine, an endogenous lipid that acts as a vasorelaxant via nitric oxide and large conductance calcium-activated potassium channels. Br J Pharmacol (2010) 1.04

Altered inhibitory synaptic transmission in superficial dorsal horn neurones in spastic and oscillator mice. J Physiol (2003) 1.03

ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol (2001) 1.01

Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine. Br J Pharmacol (2009) 1.01

Actions of N-arachidonyl-glycine in a rat inflammatory pain model. Mol Pain (2007) 0.98

The glycine transporter GlyT2 controls the dynamics of synaptic vesicle refilling in inhibitory spinal cord neurons. J Neurosci (2008) 0.97

An ultrastructural study of the glycine transporter GLYT2 and its association with glycine in the superficial laminae of the rat spinal dorsal horn. Neuroscience (1997) 0.95

Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain. Pharmacol Ther (2009) 0.95

Role of glial and neuronal glycine transporters in the control of glycinergic and glutamatergic synaptic transmission in lamina X of the rat spinal cord. J Physiol (2004) 0.94

Spinal antiallodynia action of glycine transporter inhibitors in neuropathic pain models in mice. J Pharmacol Exp Ther (2008) 0.92

N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. Br J Pharmacol (2001) 0.90

The transporters GlyT2 and VIAAT cooperate to determine the vesicular glycinergic phenotype. J Neurosci (2007) 0.88

Differential effects of spinally applied glycine transporter inhibitors on nociception in a rat model of neuropathic pain. Neurosci Lett (2008) 0.86

Inhibitors of GlyT1 and GlyT2 differentially modulate inhibitory transmission. Neuroreport (2005) 0.83

Glycine transporter inhibitors as a potential therapeutic strategy for chronic pain with memory impairment. Anesthesiology (2008) 0.83

Distinct profiles of refilling of inhibitory neurotransmitters into presynaptic terminals projecting to spinal neurones in immature rats. J Physiol (2004) 0.78

Articles by these authors

Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol (2006) 1.83

The chloride permeation pathway of a glutamate transporter and its proximity to the glutamate translocation pathway. J Biol Chem (2004) 1.59

Distinct conformational states mediate the transport and anion channel properties of the glutamate transporter EAAT-1. J Biol Chem (2002) 1.30

Capsaicin activation of glutamatergic synaptic transmission in the rat locus coeruleus in vitro. J Physiol (2002) 1.29

Move to Improve: a randomized workplace trial to increase physical activity. Am J Prev Med (2009) 1.26

Mechanisms of glutamate transport. Physiol Rev (2013) 1.24

Modulation of GABA release during morphine withdrawal in midbrain neurons in vitro. Neuropharmacology (2003) 1.22

Social-cognitive correlates of physical activity in a multi-ethnic cohort of middle-school girls: two-year prospective study. J Pediatr Psychol (2009) 1.18

N-Arachidonyl-glycine inhibits the glycine transporter, GLYT2a. J Neurochem (2006) 1.18

Actions of N-arachidonyl-glycine in a rat neuropathic pain model. Neuropharmacology (2007) 1.17

GABA transporter currents activated by protein kinase A excite midbrain neurons during opioid withdrawal. Neuron (2005) 1.15

Creating safer workplaces: assessing the determinants and role of safety climate. J Safety Res (2004) 1.14

Position of the third Na+ site in the aspartate transporter GltPh and the human glutamate transporter, EAAT1. PLoS One (2012) 1.13

Primary afferents with TRPM8 and TRPA1 profiles target distinct subpopulations of rat superficial dorsal horn neurones. Br J Pharmacol (2009) 1.09

Rostral ventromedial medulla neurons that project to the spinal cord express multiple opioid receptor phenotypes. J Neurosci (2002) 1.09

Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine. Biochem Pharmacol (2008) 1.05

Glutamate spillover modulates GABAergic synaptic transmission in the rat midbrain periaqueductal grey via metabotropic glutamate receptors and endocannabinoid signaling. J Neurosci (2008) 1.04

Loss-of-function mutations in the glutamate transporter SLC1A1 cause human dicarboxylic aminoaciduria. J Clin Invest (2010) 1.04

Serotonergic and nonserotonergic dorsal raphe neurons are pharmacologically and electrophysiologically heterogeneous. J Neurophysiol (2004) 1.02

Dose relations between goal setting, theory-based correlates of goal setting and increases in physical activity during a workplace trial. Health Educ Res (2009) 0.98

Actions of N-arachidonyl-glycine in a rat inflammatory pain model. Mol Pain (2007) 0.98

Mutations in transmembrane domains 5 and 7 of the human excitatory amino acid transporter 1 affect the substrate-activated anion channel. Biochemistry (2007) 0.97

Glutamate transporter variants reduce glutamate uptake in Alzheimer's disease. Neurobiol Aging (2010) 0.95

Postsynaptic actions of substance P on rat periaqueductal grey neurons in vitro. Neuropharmacology (2005) 0.94

Muscarinic modulation of synaptic transmission via endocannabinoid signalling in the rat midbrain periaqueductal gray. Mol Pharmacol (2008) 0.93

Do intervention fidelity and dose influence outcomes? Results from the move to improve worksite physical activity program. Health Educ Res (2009) 0.92

N-acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets. Br J Pharmacol (2010) 0.91

Zn2+ inhibits glycine transport by glycine transporter subtype 1b. J Biol Chem (2004) 0.91

Presynaptic gating of excitation in the dorsal raphe nucleus by GABA. Proc Natl Acad Sci U S A (2013) 0.90

Worksite translation of the Diabetes Prevention Program: formative research and pilot study results from FUEL Your Life. Health Promot Pract (2012) 0.89

The position of an arginine residue influences substrate affinity and K+ coupling in the human glutamate transporter, EAAT1. J Neurochem (2010) 0.89

Menthol enhances phasic and tonic GABAA receptor-mediated currents in midbrain periaqueductal grey neurons. Br J Pharmacol (2014) 0.88

Substance P drives endocannabinoid-mediated disinhibition in a midbrain descending analgesic pathway. J Neurosci (2009) 0.88

Multiple metabotropic glutamate receptor subtypes modulate GABAergic neurotransmission in rat periaqueductal grey neurons in vitro. Neuropharmacology (2004) 0.87

Using constructs of the transtheoretical model to predict classes of change in regular physical activity: a multi-ethnic longitudinal cohort study. Ann Behav Med (2010) 0.87

Sumatriptan inhibits synaptic transmission in the rat midbrain periaqueductal grey. Mol Pain (2008) 0.86

Opioid receptor modulation of GABAergic and serotonergic spinally projecting neurons of the rostral ventromedial medulla in mice. J Neurophysiol (2011) 0.86

Exon-skipping splice variants of excitatory amino acid transporter-2 (EAAT2) form heteromeric complexes with full-length EAAT2. J Biol Chem (2010) 0.85

The role of cation binding in determining substrate selectivity of glutamate transporters. J Biol Chem (2008) 0.85

Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. Clin Exp Pharmacol Physiol (2007) 0.85

Effectiveness of a healthy work organization intervention: ethnic group differences. J Occup Environ Med (2004) 0.85

Arachidonic acid and anandamide have opposite modulatory actions at the glycine transporter, GLYT1a. J Neurochem (2003) 0.84

Molecular determinants for functional differences between alanine-serine-cysteine transporter 1 and other glutamate transporter family members. J Biol Chem (2013) 0.84

Cholecystokinin exerts an effect via the endocannabinoid system to inhibit GABAergic transmission in midbrain periaqueductal gray. Neuropsychopharmacology (2011) 0.83

Extracellular loops 2 and 4 of GLYT2 are required for N-arachidonylglycine inhibition of glycine transport. J Biol Chem (2009) 0.83

A channel in a transporter. Clin Exp Pharmacol Physiol (2005) 0.83

Dynamics of forward and reverse transport by the glial glycine transporter, glyt1b. Biophys J (2005) 0.82

Glycine transporter 1 associates with cholesterol-rich membrane raft microdomains. Biochem Biophys Res Commun (2009) 0.81

Effect of the cannabinoid ajulemic acid on rat models of neuropathic and inflammatory pain. Neurosci Lett (2005) 0.81

Cellular actions of somatostatin on rat periaqueductal grey neurons in vitro. Br J Pharmacol (2004) 0.81

Molecular identification and characterization of three isoforms of tachykinin NK(1)-like receptors in the cane toad Bufo marinus. Am J Physiol Regul Integr Comp Physiol (2004) 0.80

Dissociation of μ- and δ-opioid inhibition of glutamatergic synaptic transmission in superficial dorsal horn. Mol Pain (2010) 0.79

Developmental changes in the alpha-adrenergic responses of rat periaqueductal grey neurons. Neuroreport (2003) 0.79

Making work safer: testing a model of social exchange and safety management. J Safety Res (2010) 0.78

Exploring relationships among anger, perceived organizational support, and workplace outcomes. J Occup Health Psychol (2009) 0.78

Endocannabinoid modulation by FAAH and monoacylglycerol lipase within the analgesic circuitry of the periaqueductal grey. Br J Pharmacol (2014) 0.77

Site-directed mutagenesis in the study of membrane transporters. Methods Mol Biol (2010) 0.77

Site-directed mutagenesis in the study of membrane transporters. Methods Mol Biol (2003) 0.77

Modulation of glutamate and glycine transporters by niflumic, flufenamic and mefenamic acids. Neurochem Res (2009) 0.77

Effects of L-glutamate transport inhibition by a conformationally restricted glutamate analogue (2S,1'S,2'R)-2-(carboxycyclopropyl)glycine (L-CCG III) on metabolism in brain tissue in vitro analysed by NMR spectroscopy. Neurochem Res (2002) 0.76

Postsynaptic mGluR mediated excitation of neurons in midbrain periaqueductal grey. Neuropharmacology (2012) 0.76

Receptors: cannabis medicine without a high. Nat Chem Biol (2011) 0.75

Effect of Intensity and Program Delivery on the Translation of Diabetes Prevention Program to Worksites: A Randomized Controlled Trial of Fuel Your Life. J Occup Environ Med (2016) 0.75

Correction: Identification of a 3rd Na+ Binding Site of the Glycine Transporter, GlyT2. PLoS One (2016) 0.75

Humanizing mice: catching up with elusive B1 receptors. Br J Pharmacol (2005) 0.75

A Prospective Programmatic Cost Analysis of Fuel Your Life: A Worksite Translation of DPP. J Occup Environ Med (2016) 0.75

Individual reactions to high involvement work processes: investigating the role of empowerment and perceived organizational support. J Occup Health Psychol (2009) 0.75

A model of union participation: the impact of perceived union support, union instrumentality, and union loyalty. J Appl Psychol (2007) 0.75

Cannabis constituent synergy in a mouse neuropathic pain model. Pain (2017) 0.75

Serotonergic modulation of neuronal activity in rat midbrain periaqueductal gray. J Neurophysiol (2013) 0.75

Molecular Determinants for Substrate Interactions with the Glycine Transporter GlyT2. ACS Chem Neurosci (2017) 0.75

Association of comorbid mental health symptoms and physical health conditions with employee productivity. J Occup Environ Med (2009) 0.75